PepGen Inc. 2025 Q2 10-Q Filing Summary
Business Context and Reporting Period
PepGen Inc. is a clinical-stage biotechnology company developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. This report covers the quarterly period ended June 30, 2025. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. As of August 1, 2025, there were 32,799,724 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(23.1) million | $(28.3) million | $(53.3) million | $(46.4) million |
| Operating Expenses | $23.9 million | $30.4 million | $55.3 million | $50.2 million |
| Research & Development | $18.4 million | $25.1 million | $43.8 million | $40.0 million |
| General & Administrative | $5.5 million | $5.4 million | $11.5 million | $10.4 million |
| Cash & Cash Equivalents | $35.1 million | $49.4 million (Dec 31, 2024) | $35.1 million | $49.4 million (Dec 31, 2024) |
| Marketable Securities | $39.6 million | $70.8 million (Dec 31, 2024) | $39.6 million | $70.8 million (Dec 31, 2024) |
| Total Liquidity (Cash + Securities) | $74.7 million | $120.2 million (Dec 31, 2024) | $74.7 million | $120.2 million (Dec 31, 2024) |
| Accumulated Deficit | $(324.8) million | $(271.5) million (Dec 31, 2024) | $(324.8) million | $(271.5) million (Dec 31, 2024) |
Note: All figures in millions unless otherwise noted. The filing does not provide specific margin data as the company has no revenue.
Material Changes vs. Prior Period
- Program Discontinuation: In May 2025, the company voluntarily discontinued development of its Duchenne muscular dystrophy (DMD) candidate, PGN-EDO51, after Phase 2 data (CONNECT1 study) showed insufficient dystrophin protein levels despite favorable safety. This decision led to wind-down costs included in Q2 R&D expenses.
- Expense Reduction: Q2 2025 operating expenses decreased by $6.5 million compared to Q2 2024, primarily due to reduced manufacturing costs and preclinical costs following the DMD program discontinuation, partially offset by wind-down charges and a $0.7 million non-cash impairment of lab equipment.
- Liquidity Decline: Total cash, cash equivalents, and marketable securities decreased from $120.2 million at year-end 2024 to $74.7 million at June 30, 2025, driven by operating cash outflows of $46.5 million for the six-month period.
- Legal Proceedings: A putative shareholder class action lawsuit was filed on June 9, 2025, alleging misrepresentations regarding PGN-EDO51. The company intends to defend vigorously and has not recorded a liability.
Guidance, Outlook, and Risks
- Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for one year from the filing date. Current cash resources are projected to fund operations only into the second quarter of 2026.
- Strategic Focus: The company is pivoting to focus exclusively on PGN-EDODM1 for the treatment of myotonic dystrophy type 1 (DM1). The Phase 1 FREEDOM study concluded dose escalation at 15 mg/kg, with data expected in Q4 2025. The Phase 2 FREEDOM2 study is ongoing.
- Capital Needs: The company will require substantial additional funding to advance PGN-EDODM1 and sustain operations. Failure to raise capital could force delays, scaling back, or discontinuation of programs.
- Risk Factors: Key risks include the unproven nature of the EDO platform, reliance on third-party manufacturers, potential for clinical trial failure (as seen with PGN-EDO51), and the impact of the pending securities litigation.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for funding exhaustion (projected Q2 2026) and the company's immediate plans for capital raising (e.g., equity offerings, partnerships).
- PGN-EDODM1 Data: Monitor the upcoming Q4 2025 data release from the 15 mg/kg cohort of the FREEDOM Phase 1 study for safety and splicing correction efficacy.
- Legal Exposure: Track the status of the Johnny Karam v. PepGen Inc. class action lawsuit filed in June 2025 regarding PGN-EDO51 disclosures.
- Wind-Down Costs: Review future quarters for the magnitude of remaining costs associated with winding down the DMD program and the impact on the burn rate.
- Regulatory Status: Confirm the status of regulatory authorizations for the FREEDOM2 Phase 2 study in the U.S., given previous clinical holds on the company's programs.